Skip to content

Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform

April 3, 2026 · 34 min

Show notes

The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting serious efforts into solving.
Mahony, one of the major influential figures in U.K. biotech, is a senior partner in growth investments at Novo Holdings, and was until December chair of the U.K.’s BioIndustry Association (BIA). In conversation with BioCentury Editor in Chief Simone Fishburn on The BioCentury Show, Mahony discussed the future of U.K. and European biotech, and the intersection of reforms related to financing and clinical trials, as well as the need for a rethink on drug pricing.

View full story: https://www.biocentury.com/article/658997

#UKBiotech #BiotechInnovation #DrugPricing #HealthcareReform #LifeSciencesPolicy

00:00 - Introduction
01:40 - U.K. Clinical Trial Reform
04:23 - Funding U.K. Biotech
10:40 - Propagating Innovation
15:08 - Measuring Progress
18:22 - Drug Pricing
22:40 - Scaling Europe’s Biotechs
25:16 - AI in Biotech

All episodes of The BioCentury Show

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.